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ABSTRACT
Negative lymph node (NLN) count has been recognized as a prognostic indicator 
in various cancers. However, the relationship between NLN count and the prognosis 
of cervical cancer is still unknown. In this study, 10, 500 cervical cancer patients after 
radical surgery were selected from Epidemiology and End Results Program (SEER) 
data. Clinicopathological characteristics were collected for analysis, including year 
of diagnosis, age, race, grade, primary site, FIGO stage and cause specific survival 
(CSS). Univariate and multivariate Cox proportional hazards model was used to assess 
risk factors for survival of patients. X-tile plots identified 6 as the optimal cutoff 
value of NLN count to divide patients into high and low risk subsets in terms of CSS 
(χ2 = 183.95, P < 0.001). The rate of 5-year CCS of cervical cancer patients was 
improved with an increase in NLN count from 0 to 23 (all P < 0.001). NLN count was 
validated as an independently prognostic factor by the multivariate Cox analysis (HR: 
1.571, 95% CI: 1.370~1.801, P < 0.001). Subgroup analysis showed that NLN count 
was a prognosis factor in FIGO stage I (χ2=35.023, P < 0.001), stage II (χ2 = 12.910,  
P < 0.001), stage III + IV (χ2 = 9.732, P = 0.002) and unknown stage (χ2 = 16.654,  
P < 0.001). Conclusively, this study demonstrated the NLN count was an independent 
prognostic factor for cervical cancer patients.
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INTRODUCTION
Cervical cancer is the fourth most common female 
malignancy worldwide [1–4]. For women with early-stage 
disease, radical hysterectomy and pelvic lymphadenectomy 
are the standard treatments and regional lymph node 
dissection is important to the survival outcome. Despite 
the lymph node status does not affect the staging of 
cervical cancer in the current International Federation of 
Gynecology and Obstetrics (FIGO) staging system [5], 
recent studies have revealed that the lymph node status 
such as lymph node ratio have prognostic value for survival 
of patients with cervical cancer [6–11]. The node-positive 
cervical cancer is heterogeneous and the prognosis of these 
patients cannot be stratified by the definite node-stage. The 
concept of negative lymph node (NLN) counts has attracted 
attention recently. NLN count can serve as a prognostic 
indicator in various cancers, such as colon [12], breast [13], 
esophagus [14] and gastric [15]. However, the correlation 
between NLN count and patient prognosis in cervical cancer 
is not fully studied. This retrospective study investigated 
the relationship between NLN counts and survival of 
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cervical cancer patients who received radical surgery. We 
used Surveillance Epidemiology and End Results (SEER) 
database to investigate this association, and determine the 
optimal cutoff value of NLN counts. 
RESULTS
Demographic and clinicpathological 
characteristics in SEER database
In total, we selected 10, 500 eligible patients with M0 
cervical cancer who received radical surgery from 2004 to 
2012. All patients did not receive neoadjuvant therapy. The 
median age of patients was 43 years (mean, 44.80 ± 12.91 
years). The median survival time was 54 months in SEER-
data. There were 1, 135 patients with NLN counts ranging 
from 0 to 6, and 9, 365 patients with NLN counts 7 or 
more than 7. These were 69.93% (7, 343/10, 500), 9.55% 
(1, 003/10, 500), 2.49% (261/10, 500), 0.30% (32/10, 500) 
and 17.72% (1, 861/10, 500) patients in FIGOI, II, III, IV 
and unknown stage, respectively. Since minimal cases in 
FIGO III and IV, we combined data of FIGO III and IV in 
the subsequent data analysis.
The demographic and tumor characteristics of 
patients were summarized in Table 1. A total of 31.15% (3, 
271/10, 500) patients received postoperative radiotherapy. 
The NLN number was correlated with the year of 
diagnosis, age, race, grade, histologic type, FIGO stage 
and radiation after surgery (all P < 0.05).
The optimal cutoff points for NLNs determined 
by X-tile program
We analyzed the prognostic outcome utilizing 
various NLN count ranging from 0 to 23 to assess the 
impact of different NLN count on CSS. The 5-year CSS 
was calculated for patients with NLNs number or more 
nodes and less than NLN nodes. Table 2 demonstrated that 
NLN count was a prognosis factor (all P < 0.001). The 
5-year CSS rate increased from 40.8% to 91.4%. 
As shown in Figure 1, X-tile plots were constructed 
and the maximum χ2 log-rank value of 182.842 (6 as the 
NLN count, P < 0.001) was produced, applying 6 as the 
optimal cutoff value to divide the patients into high and 
low risk subsets in terms of CSS. Compared to patients 
with NLN count ≤6, patients with NLN count >6 showed 
a significant improvement in 3 and 5-year CSS of 11.30% 
and 12.60%, respectively (Table 3).
Impact of the number of NLNs on CSS in the 
patients with cervical cancer
Univariate analysis revealed that the number of 
NLNs (P < 0.001) and other clinicopathological factors, 
including age (P < 0.001), race (P = 0.002), grade 
(P < 0.001), primary site (P < 0.001), histologic type 
(P < 0.001), FIGO stage (P < 0.001), and radiation after 
surgery (P < 0.001) were significantly correlated with the 
prognostic outcome in cervical cancer patients (Table 3). 
According to the Multivariate Cox regression analysis, 
survival of cervical patients was improved (HR = 1.571, 
95% CI: 1.370~1.801, P < 0.001) with an increase in the 
number of NLNs, indicating the number of NLNs was an 
independent predictors of CSS (Table 3). 
Impact of the NLN count on CSS in different 
FIGO stages 
According to the FIGO staging system, patients from 
SEER-data were divided into 5 subgroups, including stage 
I, II, III, IV and unknown. Since minimal cases in FIGO 
III and IV, we combined stage III and IV in one group: 
FIGO III+IV. We then further analyzed the effects of NLN 
on survival of each subgroup. We confirmed that the NLN 
count was an independently prognostic factor in each 
subgroup using univariate analysis (all P < 0.05) (Figure 2). 
After adjusting variables, the NLN count was also validated 
as an independent survival factor in FIGO stage I (NLNs 
>6, HR: 1.685, 95% CI: 1.338~2.122; P < 0.001), FIGO 
stage II (NLNs >6, HR: 1.512, 95% CI: 1.163~1.965; 
P = 0.002), FIGO stage III + IV (NLNs >6, 1.608, 95% 
CI: 1.154~2.242; P = 0.005) and unknown stage (NLNs >6, 
HR: 1.438, 95% CI: 1.050~1.971; P = 0.024) (Table 4).
DISCUSSION
Despite the current UICC/AJCC (Union for 
International Cancer Control /American Joint Committee 
on Cancer) and FIGO staging system do not consider 
the status of lymph nodes in cervical cancer, various 
studies have confirmed that it plays an important role 
in prognostic survival of patients [16–19]. Zhou et al. 
concluded that positive LN counts had prognostic value 
in lymph node positive stage I-II of cervical cancer 
[6]. However, the lymph node ratio and the number of 
positive lymph node were affected by many factors such 
as the number of lymph node retrieved and inspected, and 
neoadjuvant therapy. If the LN retrieved was not enough, 
the prediction of survival would be inaccurate. It has 
been reported that the NLN count was an independent 
prognosis factor in colon [20, 21], gastric [22], esophageal 
[14] and so on. Although Chen et al. [11] confirmed that 
the combination of NLNs count and the ratio of positive 
and removed lymph nodes could better predict the 
postoperative survival in patients with cervical cancer, 
the association between NLN counts and survival was 
not fully explored. In this study, we found that the rate of 
5-year CCS of cervical cancer patients was improved with 
the increase of NLN count from 0 to 23 (all P < 0.001), 
and identified the optimal cutoff value for NLN count 
as 6. Furthermore, the NLN count was an independent 
prognosis factor for patients with cervical cancer of each 
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FIGO stage. Apparently, NLN count is a good supplement 
for evaluation prognosis of FIGO stage. 
Until now, there is no conclusion of mechanism of 
NLNs effecting on the prognosis of cervical cancer. Heeren 
et al. identified that an increased number of regulatory 
T cells (Treg) and the decreased CD8+ T cell/Treg ratio 
were found at both positive and negative lymph nodes in 
the regional lymph node area of cervical cancer patients, 
reflecting an immune suppressive microenvironment 
that promotes metastatic spread [23]. On the other hand, 
lymphatic micrometastasis is important to the prognosis 
of cervical cancer. Since it was difficult to find lymphatic 
micrometastasis during operation, we have to retrieve 
more NLNs to reduce the residual micrometastases and 
improve the prognosis of cervical cancer, which was 
consistent to our results. 
Extent of lymphadenectomy is a matter of debate for 
cervical cancer treatment. Various studies have examined 
whether the number of retrieved lymph nodes would 
affect survival of cervical cancer patients. Lim et al. 
Table 1: Baseline demographic and tumor characteristics of patients with cervical cancer in SEER database
Parameter Characteristic N NLN = 0~6 NLN = 7~ χ2 P value
Year of diagnosis 9.597 0.002
2004–2008 6656 672 5984
2009–2012 3844 463 3381
Age 60.255 0.000
<60 9236 918 8318
≥60 1264 217 1047
Race 56.815 0.000
White 8389 829 7560
Black 956 170 786
Others 1155 136 1019
Grade 20.861 0.000
I/II 4955 466 4489
III/IV 3394 395 2999
Unknown 2151 274 1877
Primary Site 0.649 0.885
Endocervix 2377 256 2121
Exocervix 338 33 305
Overlapping lesion 343 40 303
Cervix uteri 7442 806 6636
Histologic type 9.019 0.011
Squamous cell 
carcinoma
7377 841 6536
Adenocarcinoma 2901 274 2627
Mucinous 
adenocarcinoma
222 20 202
FIGO stage 256.214 0.000
I 7343 644 6699
II 1003 184 819
III 261 89 172
IV 32 11 21
Unknown 1861 207 1654
Radiation 168.765 0.000
No radiation 7299 590 6639
Radiation after 
surgery
3271 545 2726
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[24] found that the number of retrieved lymph nodes 
was an independent prognostic factor for cervical cancer 
treatment in bulky cervical cancer group. In this group, 
more than 40 lymph nodes had a significant positive 
effect on disease-free survival and overall survival using 
multivariate analysis. However, the number of retrieved 
lymph nodes was not an independent prognostic factor 
in the non-bulky cervical cancer group. Mao et al. [25] 
showed that if a standardized lymphadenectomy was 
performed, the number of lymph nodes removed was not 
an independent prognostic factor for patients with node-
negative early cervical cancer. Zhou et al. [18] found that 
the number of positive lymph nodes had prognostic value 
in cervical squamous cell carcinoma and adenosquamous 
carcinoma, but not in cervical adenocarcinoma. Also, the 
number of positive lymph nodes is an independent risk 
factor for CSS of cervical cancer patients. In addition, 
Garg et al. [26] and Srisomboon et al. [27] explored 
the impact of different treatments on the prognosis of 
early cervical cancer. But no relationship between NLN 
count and prognosis was found in the setting of cervical 
cancer previously. Lymphatic micrometastasis plays an 
important role in the prognosis of cervical cancer. Since 
it was difficult to find lymphatic micrometastasis during 
operation, more NLNs have to be retrieved to reduce 
the residual micrometastases to improve the prognosis 
of cervical cancer. Thus, NLN count may perform better 
than total lymph node count or positive lymph node for 
prediction of survival.
The relationship between lymph node count and 
outcome was controversial in the treatment of cervical 
cancer. Because the majority of patients with early stage 
cervical cancer do not have lymph node metastases. The 
extensive lymphadenectomy was unnecessary and could 
cause complications such as lymphedema [25]. Pieterse 
et al. [28] concluded that more lymph nodes retrieved is 
Table 2: Univariate analysis of the inﬂuence of different NLN count on CSS in patients with cervical cancer
NLN No. 5-year CCS χ2 P value NLN No. 5-year CCS χ2 P value
≤0 49 40.8%
160.499 0.000
≤12 3143 85.1%
80.909 0.000
>0 10451 89.6% >12 7357 91.2%
≤1 173 60.0%
173.818 0.000
≤13 3545 86.1%
57.158 0.000
>1 10327 89.8% >13 6955 91.0%
≤2 349 68.4%
169.186 0.000
≤14 3937 86.5%
55.397 0.000
>2 10151 90.1% >14 6563 91.1%
≤3 482 70.4%
214.406 0.000
≤15 4323 86.8%
51.082 0.000
>3 10018 90.3% >15 6177 91.2%
≤4 670 73.4%
220.302 0.000
≤16 4718 87.0%
50.894 0.000
>4 9830 90.4% >16 5782 91.3%
≤5 867 75.4%
213.032 0.000
≤17 5093 87.3%
40.925 0.000
>5 9633 90.6% >17 5407 91.3%
≤6 1135 78.3%
182.842 0.000
≤18 5444 87.5%
44.011 0.000
>6 9365 90.7% >18 5056 91.3%
≤7 1404 80.2%
149.141 0.000
≤19 5870 87.9%
34.635 0.000
>7 9096 90.8% >19 4630 91.2%
≤8 1709 81.7%
123.485 0.000
≤20 6202 88.0%
32.770 0.000
>8 8791 90.8% >20 4298 91.3%
≤9 2059 83.2%
100.117 0.000
≤21 6536 88.1%
28.925 0.000
>9 8441 90.9% >21 3964 91.4%
≤10 2396 84.1%
90.895 0.000
≤22 6872 88.3%
24.252 0.000
>10 8104 90.9% >22 3628 91.3%
≤11 2761 84.4%
91.926 0.000
≤23 7141 88.4%
22.362 0.000
>11 7739 91.1% >23 3359 91.4%
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related to longer survivals of patients with positive nodes. 
Similar results were found in the studies of Shah et al. 
[19] and Lim et al. [24], which concluded that early-stage 
cervical cancer patients who underwent a more extensive 
lymphadenectomy had longer survivals. In contrast, Ditto 
et al. [17] revealed that the number of lymph nodes had 
no effect on survival. The node-positive patients with 
cervical cancer are heterogeneous and the prognosis of 
these patients cannot be stratified by the definite node-
stage. Thus, the concept of NLN count may serve as a 
prognostic indicator in various cancers. 
This study has several limitations. Firstly, different 
operative approaches, doctors and even pathologist would 
affect lymph nodes harvest, which cannot be adjusted in 
analysis. Secondly, the SEER database does not have the 
information of subsequent therapy including adjuvant 
chemotherapy, radiotherapy and targeted therapy, co-
morbidities and recurrence, which may also impact 
patients’ survival outcome. Thirdly, the SEER database 
lacks detailed description of preoperative clinical grading 
and response to treatment. Despite these potential 
limitations, this study demonstrated that the NLN count 
was an independent prognostic predictor for patients with 
cervical cancer. And 6 was identified as the optimal cutoff 
value of NLN count to divide patients into high and low 
risk subsets in terms of CSS. NLNs count could be a good 
supplement for evaluating prognosis of UICC/AJCC and 
FIGO stage of cervical cancer.
MATERIALS AND METHODS
Patient selection 
The SEER database and SEER-stat software 
(SEER*Stat 8.3.2) were used to search cervical cancer 
with M0 after radical surgery between 2004 and 2012 
Figure 1: X-tile analysis of survival data from the SEER registry. X-tile analysis was performed using patient data, equally 
divided into training and validation sets, from the SEER registry. X-tile plots of the training sets are shown in the left panels, with plots 
of matched validation sets shown in the smaller inset. The optimal cut-point highlighted by the black circle in the left panels is shown on 
a histogram of the entire cohort (middle panels), and a Kaplan-Meier plot (right panels). P values were determined using the cutoff point 
defined in the training set and applying it to the validation set. (The optimal cutoff value for NLN count is 6, χ2 = 183.95, P < 0.001).
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with a known age (≥18). Years of diagnosis, age, race, 
grade, primary site, FIGO stage and CSS were extracted 
from the SEER database. Histological types were limited 
to squamous cell carcinoma (8070/3), adenocarcinoma 
(8140/3) and mucinous adenocarcinoma (8141/3, 8142/3). 
Survival time was calculated from the date of diagnosis to 
the date of cancer-specific death. The exclusion criterions 
included: age<18, receiving neoadjuvant therapy, no 
evaluation of histological type, multiple malignant 
neoplasms, died within 30 days or information on CSS 
and survival months unavailable.
Statistical analysis
The NLNs cutoff points were determined using the 
X-tile program (http://www.tissuearray.org/rimmlab/), 
Table 3: Univariate and multivariate survival analysis of cervical cancer patients who received radical surgery
Parameter Characteristic 3-year CCS
5-year 
CCS
Univariate analysis Multivariate analysis
Log rank 
χ2 test
P HR (95%CI) P
Year of diagnosis 1.743 0.187 NI
2004–2008 88.1% 83.5%
2009–2012 88.9% 82.3%
Age 77.726 0.000 0.002
<60 89.1% 84.2% Ref
≥60 83.1% 74.5% 0.805 (0.699~0.926) 0.002
Race 12.908 0.002 0.009
White 88.8% 83.6% Ref
Black 85.8% 79.1% 1.064 (0.895~1.265) 0.482
Others 87..8% 82.3% 1.350 (1.082~1.685) 0.008
Grade 156.785 0.000 0.000
I/II 90.6% 85.5% Ref
III/IV 83.0% 76.6% 1.242 (1.037~1.488) 0.019
Unknown 91.9% 87.4% 1.966 (1.645~2.349) 0.000
Primary Site 24.410 0.000 0.266
Endocervix 91.5% 86.2% Ref
Exocervix 87.9% 84.3% 0.858 (0.732~1.006) 0.059
Overlapping lesion 87.8% 83.1% 0.987 (0.719~1.354) 0.934
Cervix uteri 87.4% 82.0% 0.881 (0.646~1.200) 0.421
Histologic type 70.867 0.000 0.000
Squamous cell carcinoma 87.0% 81.3% Ref
Adenocarcinoma 92.2% 87.9% 0.473 (0.353~0.633) 0.000
Mucinous 
adenocarcinoma
84.7% 76.1% 0.544 0.404~0.733) 0.000
FIGO stage 934.468 0.000 0.000
I 92.4% 88.0% Ref
II 73.7% 64.7% 0.647 (0.560~0.748) 0.000
III 58.2% 48.7% 1.406 (1.192~1.658) 0.000
IV 21.8% 15.6% 2.367 (1.908~2.937) 0.000
Unknown 85.9% 79.2% 6.989 (4.644~10.518) 0.000
Radiation 608.573 0.000 0.000
No radiation 92.9% 89.0% Ref
Radiation after surgery 78.4% 69.9% 0.321 (0.282~0.365) 0.000
NLN 127.645 0.000 0.000
0~6 78.3% 71.8% Ref
7~ 89.6% 84.4% 1.571 (1.370~1.801) 0.000
NI: not included in the multivariate survival analysis.
Oncotarget2816www.impactjournals.com/oncotarget
Figure 2: Log-rank tests of CSS comparing patients with NLNs (≤6 VS >6) for (A) FIGO stage I: χ2 = 35.023, P < 0.001; (B) FIGO stage 
II: χ2 = 12.910, P < 0.001; and (C) FIGO stage III + IV: χ2 = 9.732, P = 0.002 and (D) Unknown stage: χ2 = 16.654, P < 0.001.
Table 4: Univariate and multivariate analysis of NLN status on CSS of cervical cancer based on different cancer stage
Parameter NLN 3-year CCS
5-year 
CCS Univariate analysis Multivariate analysis
Log rank χ2 test P HR(95%CI) P
FIGO stage 
Stage I 35.023 0.000 0.000
0~6 89.0% 83.2% Ref
7~ 92.7% 88..5% 1.685 (1.338~2.122) 0.000
Stage II 12.910 0.000 0.002
0~6 60.3% 54.9% Ref
7~ 76.7% 66.9% 1.512 (1.163~1.965) 0.002
Stage III + IV 9.732 0.002 0.005
0~6 46.0% 33.0% Ref
7~ 58.5% 51.3% 1.608 (1.154~2.242) 0.005
Unknown 
stage
16.654 0.000 0.024
0~6 76.8% 70.0% Ref
7~ 87.1% 80.4% 1.438 (1.050~1.971) 0.024
P-values refer to comparisons between two groups and were adjusted for age, race, grade, histologic type, FIGO stage and 
radiation after surgery as covariates.
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which identified the cutoff value with the minimum 
P values from log-rank χ2 statistics for the categorical 
NLNs in terms of CSS. 
The X-tile plot illustrates the presence of substantial 
tumor subpopulations and shows the robustness of 
the relationship between a biomarker and outcome by 
construction of a two dimensional projection of every 
possible subpopulation [29]. In our data, the variables, 
negative lymph node count and cancer specific survival 
were used. X-tile plots provide a single, global assessment 
of every possible way of dividing a population into low/
high or low/medium/high level marker expressions. 
X-tile data are presented in a right grid where each 
point represents a different cut-point. The intensity of 
the color of each cutoff point represents the strength of 
the association. The X-tile software allows the user to 
move a cursor across the grid and provides an “on-the-
fly” histogram of the resulting population subsets along 
with an associated Kaplan-Meier curve [30]. Baseline 
characteristics were compared using the χ2 test for 
nominal variables. Survival curves were generated using 
Kaplan-Meier analyses, and the differences between the 
curves were analyzed by log-rank test. Cox regression 
models were built for analysis of risk factors for survival 
outcomes. Statistical analyses were performed using the 
statistical software package SPSS for Windows, version 
19.0 (SPSS Inc., Chicago, IL). All P values were two-
sided. P < 0.05 was considered statistically significant.
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